AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 06/14/23

- Adds first ready-to-use presentation of key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma - Represents a high value, complex product launch for Amneal’s expanding injectable portfolio Amneal Pharmaceuticals, Inc. (N...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2023 Jefferies Healthcare Conference held on June 7, 2023 in New York City. Mr...

2023-05-18 12:07:41 ET Are you looking at the stock market today and preparing to identify the best penny stocks to buy now? If you are, you’re not alone. With the robust nature of bullish optimism this week, the “risk-on” trade is back for the time being. Fears...

2023-05-16 13:59:00 ET When it comes to investing, penny stocks hold a unique allure. These stocks represent shares of small companies that typically trade below $5 per share, with some finding their place on major exchanges like the NYSE and Nasdaq. However, others trade in the over-th...

- Third of three approved U.S. oncology biosimilars Amneal has launched Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of FYLNETRA™ (pegfilgrastim-pbbk), a biosimilar referencing Neulasta ...

2023-05-05 13:25:23 ET Amneal Pharmaceuticals, Inc. (AMRX) Q1 2023 Earnings Conference Call May 05, 2023 08:30 AM ET Company Participants Tony DiMeo - Head-Investor Relations Chirag Patel - President & Co-Chief Executive Officer Chintu Patel - Co-Chief Execut...

2023-05-04 12:40:44 ET Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q1 earnings results on Friday, May 5th, before market open. The consensus EPS Estimate is $0.10 (-16.7% Y/Y) and the consensus Revenue Estimate is $542.18M (+9.0% Y/Y). Over the last ...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 22nd Annual Needham Virtual Healthcare Conference held on April 19, 2023. Mr. ...

2023-04-17 06:41:26 ET Amneal Pharmaceuticals ( NYSE: AMRX ) reports Q1 preliminary net revenue of $550 million to $560 million up 12% Y/Y against $529.36M consensus. Q1 loss before income taxes of $10M to $0, an improvement of ~50% Y/T. Adjusted EBITDA of $115M to $1...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced certain unaudited preliminary financial results for the first quarter ended March 31, 2023. The Company is also affirming financial guidance for the year ending December 31, 2023, which w...